title: Impact of new therapeutics for hepatitis C virus infection in incarcerated populations.
abstract: Inmate populations bear a disproportionate share of the burden of hepatitis C virus (HCV) infection. With more than 90% of prisoners released back to their communities within a few years of sentencing, incarceration can be viewed as an opportunity to provide HCV screening and therapeutic interventions to benefit the individual, reduce the costs of HCV management to the health care system from a societal perspective, and improve overall public health. Although optimal medical management of HCV within prison settings would increase the current cost of correctional health care, it could decrease transmission within the community, reduce overall disease burden, and lower the future societal health care costs associated with end-stage liver disease. Nonetheless, most prison systems treat only a small fraction of infected inmates. Current and emerging therapeutic agents will cure HCV infection in the vast majority of patients. Mathematical modeling also shows that expanded HCV screening and treatment are cost-effective from the societal perspective. In this article, we will describe appropriate treatment regimens, propose strategies to lessen the burden of these costly HCV therapies on correctional health care systems, and address the challenges of expanded HCV screening in correctional settings.
authors.affiliation: Emory University, Atlanta, GA, USA.
authors.forename: Anne S
authors.initials: AS
authors.lastname: Spaulding
authors.forename: Arthur Y
authors.initials: AY
authors.lastname: Kim
authors.forename: Amy Jo
authors.initials: AJ
authors.lastname: Harzke
authors.forename: Jean C
authors.initials: JC
authors.lastname: Sullivan
authors.forename: Benjamin P
authors.initials: BP
authors.lastname: Linas
authors.forename: Arthur
authors.initials: A
authors.lastname: Brewer
authors.forename: Jeff
authors.initials: J
authors.lastname: Dickert
authors.forename: Barbara H
authors.initials: BH
authors.lastname: McGovern
authors.forename: Lara B
authors.initials: LB
authors.lastname: Strick
authors.forename: Robert
authors.initials: R
authors.lastname: Trestman
authors.forename: Warren J
authors.initials: WJ
authors.lastname: Ferguson
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D004359:Drug Therapy, Combination / Q000191:economics / Q000379:methods; D019698:Hepatitis C, Chronic / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology*; D006801:Humans; D017053:Infection Control / Q000191:economics / Q000379:methods; D008403:Mass Screening / Q000191:economics / Q000379:methods; D008962:Models, Theoretical; D011329:Prisoners
chemical_list: D000998:Antiviral Agents